Article Figures & Data
Figures
- FIG. 1.
Treatment and blood sampling sequences during the study.
- FIG. 2.
QC PCR analysis of MxA mRNA in PBMCs from patient 1. PBMCs were collected before and at 24 and 48 h after a single injection of rIFN-a2a, (C)IFN, and LeIFN. Serial logarithmic dilutions of extracted RNA, normalized by using b-actin mRNA as a control, were mixed with 2 3 106 copies of the internal competitor and subjected to RT-PCR (for details, see Materials and Methods). The arrows indicate the equivalence points.
- FIG. 3.
QC PCR analysis of MxA mRNA in PBMCs from patient 2. PBMCs were collected before and at 24 and 48 h after a single injection of rIFN-α2a, (C)IFN, and LeIFN. Serial logarithmic dilutions of extracted RNA, normalized by using β-actin mRNA as a control, were mixed with 2 × 106 copies of the internal competitor and subjected to RT-PCR (for details, see Materials and Methods). The arrows indicate the equivalence points.
- FIG. 4.
Neopterin protein levels in the sera of patients 1 (A) and 2 (B). Serum neopterin concentrations were measured by enzyme-linked immunosorbent assay before and at 24 and 48 h after a single injection of rIFN-α2a, (C)IFN, and LeIFN. Bars represent means ± standard deviations for three separate determinations.
- FIG. 5.
Increases in serum neopterin levels at 24 and 48 h compared with that at the baseline in NAB-negative patients with EMC after a single injection of recombinant IFN-α2a. Each histogram represents the mean ± standard deviations for five patients. ∗, P < 0.05 compared with the level at time zero.
Tables
- TABLE 1.
Neutralizing activities of sera from two patients with severe type II EMC resistant to rIFN-α2aa
Patient no. Neutralization titer against: rIFN-α2a (C)IFN LeIFN 1b 950 ± 190 63 ± 10 NDc 1d 486 ± 80 30 ± 5 ND 1e 1379 ± 29 87 ± 4 <10 2b 47 ± 11 <10 ND 2d 1,300 ± 260 87 ± 20 ND 2e 1,600 ± 399 87 ± 2 <10 ↵a Sera for detection of neutralizing activity were collected before the injection of the different IFN-α preparations (see text for details). The data are expressed as the means ± standard deviations for three separate determinations.
↵b Serum was analyzed before the injection of rIFN-α2a.
↵c ND, not done.
↵d Serum was analyzed before the first injection of (C)IFN.
↵e Serum was analyzed before the first injection of LeIFN.
- TABLE 2.
Specificities of NABs to IFN-α in sera from two patients with severe type II EMC resistant to rIFN-α2aa
IFN-α subtype Neutralizing activity (t1/10) against subtypes of natural IFN-α Patient 1 Patient 2 1 24 ± 8 <10 2a 1,379 ± 29 1,600 ± 399 5 112 ± 64 108 ± 3 6 1,124 ± 11 189 ± 8 7a 14 ± 5 33 ± 11 7c 83 ± 53 136 ± 76 8b <10 <10 10a 14 ± 3 49 ± 20 14a <10 84 ± 7 17a 37 ± 2 43 ± 4 21a 22 ± 13 <10 ↵a Sera for detection of the neutralizing activity against the different IFN-α preparations were collected before the injection of LeIFN (see text for details). The data are expressed as the means ± standard deviations for three separate experiments.
